Scientific Programme

Monday, 22 June 2009

09.00	Opening session
	P-A. Abrahamsson, Malmö (SE), Secretary-General EAU
	P.F.A. Mulders, Nijmegen (NL), Chairman EAURF
	J.A. Schalken, Nijmegen (NL), PRIMA Consortium
	_______________________________________
09.15 – 10.30	Molecular genetics of prostate cancer
	Chair: G. Jenster, Rotterdam (NL)
09.15 – 09.40	Identification of common genetic variants that affect the risk of prostate cancer T. Rafnar, Reykjavic (IS)
09.40 – 10.05	Integration of high-throughput technologies to identify drug targets and new therapeutic options for prostate cancer. O. Kallioniemi, Helsinki (FI)
10.05 - 10.30	microRNAs in diagnosis and therapy T. Visakorpi, Tampere Yliopisto (FI)
	_______________________________________
10.30	Break
11.00 – 12.05	From molecular target to clinical molecular diagnostics Chair: A. Bjartell, Malmö (SE)
11.00 – 11.15	What is the best practice in bio-banking? F.C. Hamdy, Oxford (GB)
11.15 – 11.40	Clinical validation and implementation of new biomarkers E.A.M. Schenk-Braat, Rotterdam (NL)
11.40 – 12.05	Challenges for biomarkers after ERSPC and REDUCE J.A. Schalken, Nijmegen (NL)
	_______________________________________
12.05	Round table Biomarkers in prostate cancer, where do we go? Chair: L.A. Kiemeney, Nijmegen (NL) Panelists: F.C. Hamdy, T. Rafnar, J.A. Schalken,E.A.M. Schenk-Braat, T. Visakorpi
	_______________________________________
13.00 – 14.00	Lunch and poster viewing
14.00 – 16.10	Research- and training networks Chair: P.F.A. Mulders, Nijmegen (NL)
14.00 – 14.20	The EC perspective M.J. Vidal-Ragout, Brussels (BE), (European Commission)
14.20 – 14.40	The NCI SPORE programs TBC A. Hruszkewycz, Bethesda (US)
14.40 – 15.00	What does the patient with prostate cancer expect from us? L.J. Denis, Antwerp (BE), (Europe Uomo)
15.00 – 15.20	Training the next generation prostate cancer researches (MC training networks) C. Robson, Newcastle upon Tyne (GB)
15.20 – 15.50	Discussion: Can we integrate the networks? Chair: P.F.A. Mulders, Nijmegen (NL)
15.40 – 16.10	Presentation of Dominique Chopin Distinguished Award
	_______________________________________
16.10	Poster viewing and discussion
16.30	Continued with drinks
Tuesday, 23 June 2009
08.30 – 11.00	Targeted therapies Chair: J.A. Schalken, Nijmegen (NL)
08.30 – 09.00	The androgen receptor J. Trapman, Rotterdam (NL)
09.00 – 09.30	Tumor-bone interactions in the pathogenesis of bone metastasis G. Van Der Pluijm, Leiden (NL)
09.30 – 10.00	Optimising targeted gene therapy for prostate cancer N.J. Maitland, York (GB)
10.30 – 11.00	A critical view on targeted therapies; from magic bullet to smart bomb! J. Isaacs, Baltimore (US)
	_______________________________________
11. 00 – 11.30	Break
	Keynote lecture
11. 30 – 12.15	Meeting the challenges of translating biomarker discoveries into routine tools capable of changing clinical paradigms of patient counseling or treatment H. Lilja, New York (US)